HLA matching is a critical determinant of outcomes for patients who have undergone umbilical cord blood transplantation (UCBT). Data have been published on the importance of donor/recipient HLA mismatch direction on UCBT outcomes. HLA mismatch in the graft-versus-host (GVH) direction is defined as a donor homozygous at an HLA locus, while the recipient shares one HLA Ag with the donor. HLA mismatch in the host-versus-graft (HVG) direction is defined as a recipient homozygous with the donor sharing one HLA Ag. In our study we focused on confirming, using an independent population, whether transplantation outcomes would be different when HLA mismatch direction was considered. We analyzed 1565 patients who received a single-unit UCBT for malignant disease. Median age was 15 years and 72% of patients were transplanted for leukemia. In multivariate analysis, using the 5/6 HLAmatched population as reference, one or two HLA mismatches in the GVH or HVG direction were not associated with non-relapse related mortality and survival. On the basis of our results, there is no evidence to support a change in the current practice for cord blood unit selection.
INTRODUCTION
Several studies have shown that the number of cells is one of the most important factors for engraftment after umbilical cord blood transplant (UCBT), and that some degree of HLA mismatch is not only acceptable but also may favor both lower incidence and severity of GVHD when compared with unrelated donor transplantation. 1 It is well documented that 1 to 2 HLA mismatches defined by Ag typing level for HLA-A and -B and allele typing for DRB1 gives the same leukemia-free survival as fully matched highresolution-typed unrelated adult donors. 2 The mechanisms that could explain the mismatch tolerance are still not well understood. Among them are the lower number of T-cells infused, the immune immaturity of newborn lymphocytes and the enrichment of cord blood with regulatory T cells (Tregs) which may have a role. [3] [4] [5] In addition, maternal and paternal HLA may influence UCBT outcomes. 6, 7 Further, the importance of donor/recipient HLA mismatch direction has also been investigated. [8] [9] [10] HLA mismatch direction is classified as follows: a mismatch present in both recipient and donor is classified as bidirectional (BID). However, when the donor is homozygous for one Ag/allele in an HLA locus while only one of them is identical in a heterozygous recipient, this mismatch is classified as being in the graft-versus-host direction (GVH). Conversely, when the recipient is homozygous for one locus and only one of the HLA Ags/alleles is identical in a heterozygous donor, the mismatch is classified as being in the host-versus-graft direction (HVG). When there are two HLA mismatches, various combinations of mismatch direction are possible (Table 1) .
With the aim of investigating if HLA mismatch direction has an impact on UCBT outcomes, we analyzed 1565 patients, reported to Eurocord, receiving a single-unit UCBT for hematological malignancies.
PATIENTS AND METHODS

Data collection and population
Eurocord is a clinical research group operating on behalf of the European Blood and Marrow Transplantation (EBMT) group. Participation in this study was open to EBMT centers (n ¼ 178) performing UCBT. Data on patient, disease and transplant characteristics, and clinical outcomes were collected by standardized questionnaires for each UCBT recipient.
Inclusion criteria were as follows: (1) recipients receiving unrelated single-unit UCBT as first allogeneic transplant, (2) available HLA typing data and (3) available clinical information. We analyzed, retrospectively, 1565 patients transplanted from 1 January 1994 to 31 December 2009. The minimal follow-up time for survivors was 3 months. All patients or legal guardians provided written informed consent in accordance with the Declaration of Helsinki.
HLA typing
Confirmatory HLA typing of all cord blood units (CBUs) was performed before transplantation. According to the international standard guidelines, patients and donors were typed for HLA-A and -B at the antigenic or intermediate resolution level and for DRB1 at the allelic resolution level. HLA-C, -DQ and -DP matching were not considered for this study. Patients transplanted with three or more HLA mismatches were excluded. The association between HLA mismatch direction and clinical outcomes was analyzed independently for patients transplanted from a donor with 1 (5/6) and 2 (4/6) HLA disparities and compared with the group of recipients whose donor was 5/6 HLA compatible, classified as BID mismatch.
Definitions
Disease status was classified according to criteria from the Center for International Blood and Marrow Transplant Research. 11 Relapse of hematological malignancies patients, including those transplanted in non-remission, was defined according to the EBMT guidelines (http:// www.ebmt.org/Contents/DataManagement/Registrystructure/MED-ABdata collectionforms/Pages/MED-AB-data-collection-forms.aspx). A myeloablative conditioning (MAC) was defined as a regimen containing TBI with a dose of more than 6 Gy, a dose of oral Bu of more than 8 mg/kg, a dose of i.v. Bu of more than 6.4 mg/kg or a dose of treosulfan of at least 12 g/m 2 . Neutrophil recovery was defined as achieving ANC X0.5 Â 10 9 /L for three consecutive days. Full donor chimerism was defined as sustained donor engraftment assessed using chimerism assay (X95% donor). The timing and method of testing were at the discretion of the transplant center. Platelet recovery was defined as achieving platelet levels X20 Â 10 9 /L unsupported by platelet transfusions for 7 days. The diagnosis and grading of acute or chronic GVHD (aGVHD or cGVHD) were assigned by the transplant center using standard criteria. 12, 13 Non-relapse mortality (NRM) was defined as death without prior relapse. OS) was counted as time interval between transplantation and death due to any cause, and disease-free survival (DFS) was defined as duration of survival without recurrence of the primary disease. For this end point, both death and relapse were considered an event.
Statistical analysis
Median values and ranges were reported for continuous variables and percentages for categorical variables. The probabilities of OS and DFS were calculated using the Kaplan-Meier estimator and the log-rank test for univariate analysis.
14 Probabilities of neutrophil engraftment, grade 2-4 aGVHD and cGVHD were calculated with the cumulative incidence estimator. Multivariate analyses were performed using a Cox proportional hazards regression model for DFS and OS, and a Fine and Gray's proportional hazards regression model for neutrophil engraftment, aGVHD, cGVHD, NRM and disease recurrence. 15, 16 Variables included recipient age, donor sex, ABO compatibility, HLA compatibility and mismatch direction, number of total nucleated cells (TNC) and CD34 þ cells at both time of freezing and that of infusion, conditioning regimen and year of UCBT. Each potential risk factor was tested independently. All factors that reached a P-valuep0.20 in univariate analysis were included in the multivariate model. All models were built using a forward stepwise method. Only factors that reached a P-value p0.05 were retained in the final model. Patients were censored at time of the second transplant or, for surviving patients, at last follow-up. P-values were two-sided. Statistical analyses were performed using SPSS 18.0 statistical software (SPSS, Chicago, IL, USA) version 18, and S-Plus 8.1 (TIBCO Software, Seattle, WA, USA).
RESULTS
Patient, disease, donor and transplant characteristics Patient, donor and transplant characteristics are listed in Table 2 . Forty percent of patients were transplanted for ALL, 32% for AML, 14% for myelodysplastic syndrome and 14% for other malignant disorders. MAC was used in 1236 (81%) patients, anti-thymocyte globulin/MoAb in 1165 (80%) and hematopoietic growth factors in 1010 (76%) patients. Median follow-up time was 36 (range 3-175) months.
Cord blood units were provided by 44 Cord Blood Banks (CBB), the majority of the CBB were originally from Europe. About 10% of patients (n ¼ 158) in the current study cohort received a cord blood unit from the NYBC. As transplant centers in Europe report outcome data from their consecutive cases of UCBT recipients to Eurocord registry and not to NYBC, we can assume that an overlap of patients between the two studies is very unlikely. The majority of the transplants were performed in France (34%), Spain (26%) and Italy (19%). Donor-recipient HLA compatibility and HLA mismatch direction classification subgroups are summarized in Table 3 . One hundred and fifty-five patients (10%) were HLA identical, 647 (42%) had one HLA disparity and 763 (48%) had two HLA disparities. On the basis of HLA mismatch (MM) direction classification, recipients given a 5/6 graft were classified as 1 MM GVH (n ¼ 44; Class I MM ¼ 35 and Class II MM ¼ 9), 1 MM HVG (n ¼ 42; Class I MM ¼ 32 and Class II MM ¼ 10) and 1 MM BID (n ¼ 561) subgroups. Recipients given a 4/6 graft were classified as 2 MM (Table 4 ).
Relapse and DFS CumuIative incidence of relapse at 3 years was 32 ± 2%. In a multivariate analysis, higher relapse risk was associated with advanced disease status at time of transplantation (HR 1.50, 95% CI: 1.22-1.84, Po0.01) and with reduced-intensity conditioning (HR 1.65, 95% CI: 1.28-2.12, Po0.01). Recipients given a 6/6 graft (HR 1.54, 95% CI: 1.12-2.11, Po0.01) had higher risk of relapse incidence (Table 5) .
Overall estimated 3-year DFS was 34 ± 1% for the whole population. Multivariate analysis showed higher DFS rate for transplantation performedX2005 (HR of DFS was not associated with overall degree of HLA disparity. HLA mismatch direction was not associated with DFS (Table 5 ).
Survival and causes of death Overall OS at 3 years was 39 ± 1%. In multivariate analysis, increased survival rate was associated with year of transplantation X2005 (HR 1.41, 95% CI: 1.21-1.64, Po0.01), children (HR 1.28, 95% CI: 1.07-1.52, Po0.01), prior negative recipient's CMV serology status (HR 1.31, 95% CI: 1.13-1.51, Po0.01) and early/ intermediate disease status at time of transplantation (HR 1.58, 95% CI: 1.37-1.83, Po0.01). HLA mismatch direction was not associated with survival (Table 5) .
Nine hundred and twenty-four patients died. Fifty-eight percent of the deaths were related to UCBT complication, 38% were due to relapse or disease progression, while 4% were due to other or unknown causes. In detail, deaths related to transplant complications were as follows: 40% infections, 23% GVHD, 7% hemorrhagic complications, 7% multi-organ failure, 8% pulmonary complications, 4% veno-occlusive disease, 2% cardiac toxicity and 9% others.
DISCUSSION
In our analysis, we focused on determining whether transplantation outcomes were different when HLA mismatch direction was considered. Also, we aimed to confirm in an independent population, the previous findings on unidirectional mismatches and outcomes of UCBT. 10 Stevens reported an association between GVH direction and engraftment, but with increased risk of GVHD, and an association between HVG and graft rejection and decreased GVHD rates and, consequently, increased risk of relapse 10 However, our findings did not confirm these hypotheses. We analyzed a large series of 1565 patients with hematological malignancies and transplanted with a single CBU. In this analysis, no association between HLA mismatch and any outcome end point was found, except for an association in one subset relapse risk. In our previous studies 1, 17 and from others, number of HLA mismatches negatively has an impact on early outcomes, such as neutrophil recovery and early NRM, mainly for those patients given a 4/6 and 3/6 (not included in the present study) UCBT. However, as it positively has an impact on relapse, final outcomes such as DFS are not affected by HLA differences. Moreover, the impact of HLA was more evident when the transplant centers were not aware of the impact of cell dose. As the transplant centers choose CB units with high numbers of cells and avoid 3/6 UCBT, the impact of HLA does not seem to be as important as previously found.
Concerning HLA mismatch direction, only recipients given a 4/6 graft with BID þ HVG mismatch had higher risk of cGVHD incidence. NRM, aGVHD, DFS, OS and relapse were not associated with any HLA mismatch direction in multivariate models. Three previous reports evaluated the association between HLA mismatch direction and UCBT outcomes. [8] [9] [10] Data from Koegler's 8 and Matsuno's 9 studies regarded a small group of patients without a clear definition of unidirectional mismatches. Thus, their findings are difficult to compare with ours. Recently, Stevens et al. 1 analyzed 1202 recipients receiving single-unit UCBT and found that recipients given a graft mismatched in the GVH direction had better engraftment and lower NRM. As in the Stevens' study, one of the limitations of our analysis was that the number of 1 MM GVH and 1 MM HVG is relatively small, and the findings reported have to be more carefully addressed in larger cohort of patients.
Comparing with to our analysis, many factors could explain the difference between the results shown by the Stevens' study: (1) our analysis did not include non-malignant diseases, (2) cord blood units came for multiple banks, instead of a single CBB as in the Stevens' study, (3) differences in populations characteristics, such as the geographical origin, patients age. 1 In an attempt to explain why HLA mismatch direction did not correlate with UCBT outcomes, we have raised some hypotheses. First, the role of HLA matching is an important factor on UCBT outcomes. It has been published that a decrease of NRM is observed when additional matching of donor and recipient for HLA-C is considered. 18 Also, several studies report the importance of high-resolution typing on unrelated transplant outcomes. [19] [20] [21] However, there is a lack of studies addressing the benefit of highresolution typing in recipients of UCBT. In our analysis, we did not take into account mismatches at high resolution for class I or for HLA-C or HLA-DQ. The role for high-resolution typing and matching remains an important open question that will require studies with a large, immunogenetically well-characterized transplant population.
Our second hypothesis is related to HLA-related immunologic response. The immune mechanism that might explain whether the effects of MM direction reflect active immune reactivity from either host or CB cells or the absence of both is not well defined. In addition, the induction of immune tolerance in UCBT is not well understood, and, in fact, much of our knowledge of the immunogenetic basis of alloreactivity comes from long-standing clinical experience in the use of BM as the source of graft but, possibly, they might not be applicable to UCBT. Further, the potential role of anti-HLA Abs in engraftment was not investigated here, but recipient sensitization is likely to interact with HLA mismatches. Several studies have demonstrated that donorspecific anti-HLA Abs have a significant detrimental impact on the patient's outcome. [22] [23] [24] [25] Finally, one could argue that we have analyzed a heterogeneous group of patients with various diagnoses and disease status. However, when analyzing a homogenous subgroup of patients with acute leukemia in remission, we were not able to find any statistical difference of direction of mismatch and outcome (data not shown).
In conclusion, on the basis of our analysis, there is no evidence to support a change in the current practice for choosing CBUs, taking in account HLA mismatch direction. Moreover, other factors such as cell dose, high-resolution HLA matching, the role of noninherited maternal Ags and inherited paternal Ags 6,7 that may influence transplant outcomes need to be evaluated in larger series of patients before drawing definitive conclusions. The disparity found between our results and those previously published with a different population indicates the need for a larger cohort of a well-defined population before considering changing the current selection practices for CBUs.
